Skip to main content

BioMarin Pharmaceutical Inc.

corporate_fare Company Profile

BioMarin Pharmaceutical Inc.

BMRN·NASDAQ·Life Sciences·CIK 0001048477

BioMarin Pharmaceutical Inc. is a global rare disease biotechnology company that develops medicines for people with genetically defined conditions. Founded in 1997 and based in San Rafael, California, the company has eight commercial therapies. In 2025, BioMarin achieved $3.2 billion in total revenues, with a significant contribution from VOXZOGO. The company focuses on developing and commercializing innovative therapies for patients with serious and life-threatening rare diseases and medical conditions through internal research, partnerships, and acquisitions. BioMarin conducts strategic portfolio assessments of research and development programs to evaluate scientific merit, commercial success opportunity, and potential value creation for stockholders, which may lead to the discontinuation of programs that do not meet development thresholds. In December 2025, BioMarin entered into a definitive agreement to acquire Amicus Therapeutics, Inc. for $14.50 per share in an all-cash transaction totaling approximately $4.8 billion. This acquisition is expected to add two new therapies for Fabry disease and late-onset Pompe disease to BioMarin's commercial portfolio. The transaction is expected to close in the second quarter of 2026 and will be financed through cash on hand and approximately $3.7 billion of non-convertible debt financing.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for BMRN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • BioMarin Secures Final French FDI Clearance for Amicus Therapeutics Merger, Closing Expected April 27
  • BioMarin Seeks Shareholder Approval for Significant Equity Plan Expansion and Board Leadership Transition
  • BioMarin Discontinues Multiple Voxzogo Phase 2 Trials Citing Adverse Events
  • BioMarin Halts VOXZOGO Phase 2 Trials for Multiple Indications Due to Safety Concerns
  • FDA Expands BioMarin's Palynziq Approval to Adolescents with PKU

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$3.22B
Net Income
$348.9M
Diluted EPS
$1.80
Op. Cash Flow
$827.99M
Free Cash Flow
$724.96M
Gross Profit
$2.5B
Operating Income
$409.48M
Cash & Equivalents
$1.31B
Total Debt
$597.18M
Debt / Equity
0.10×
Net Margin
10.8%
Shares Outstanding
192.3M sh
Source: 10-K · filed 2026-02-26 · accession 0001048477-26-000004
$60.02 -0.65% today
52-week range · as of 2026-11-03 $49.26 – $70.98
Market cap
$11.7B
Volume
6.1M (2.3× avg)
3-mo avg 2.7M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed BMRN - Filings & News (Page 2)

BMRN
Apr 23, 2026, 4:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $53.91
Real-time Price: $60.02 info
Change: +$6.11 (+11%) info
Market Cap: $11.701B info
BMRN
Apr 21, 2026, 4:19 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $54.62
Real-time Price: $60.02 info
Change: +$5.40 (+10%) info
Market Cap: $11.701B info
BMRN
Mar 16, 2026, 8:38 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $57.50
Real-time Price: $60.02 info
Change: +$2.52 (+4%) info
Market Cap: $11.701B info
BMRN
Mar 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $58.51
Real-time Price: $60.02 info
Change: +$1.51 (+3%) info
Market Cap: $11.701B info
BMRN
Feb 27, 2026, 8:02 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $59.31
Real-time Price: $60.02 info
Change: +$0.7101 (+1%) info
Market Cap: $11.701B info
BMRN
Feb 26, 2026, 12:30 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $60.37
Real-time Price: $60.02 info
Change: -$0.350 (-0.58%) info
Market Cap: $11.701B info
BMRN
Feb 23, 2026, 4:08 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $62.69
Real-time Price: $60.02 info
Change: -$2.67 (-4%) info
Market Cap: $11.701B info
BMRN
Feb 12, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $59.94
Real-time Price: $60.02 info
Change: +$0.080 (+0.13%) info
Market Cap: $11.701B info
BMRN
Jan 29, 2026, 4:19 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $57.10
Real-time Price: $60.02 info
Change: +$2.92 (+5%) info
Market Cap: $11.701B info
BMRN
Jan 26, 2026, 7:54 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $56.21
Real-time Price: $60.02 info
Change: +$3.81 (+7%) info
Market Cap: $11.701B info
BMRN
Jan 12, 2026, 4:44 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $57.71
Real-time Price: $60.02 info
Change: +$2.31 (+4%) info
Market Cap: $11.701B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets